



## Scientific Letter

### Clinical Characteristics of Bronchiectasis due to Transplant-Related Immunosuppression



#### *Características clínicas de las bronquiectasias debidas a inmunosupresión post trasplante*

Dear Editor,

The real prevalence of bronchiectasis is unknown and difficult to establish.<sup>1</sup> There is limited data on this matter and the published series probably underestimate it. However, the incidence and prevalence of bronchiectasis is increasing.<sup>1</sup>

The aetiology of bronchiectasis is heterogeneous. The most common causes are idiopathic (38.1%) and post-infectious (21.2%).<sup>2</sup> Primary or secondary immunodeficiencies are responsible for 4.2–5.8% of bronchiectasis approximately.<sup>3,4</sup>

An uncommon and poorly described cause of bronchiectasis is the secondary immunodeficiency due to immunosuppressive drugs after solid organ transplantation (SOT) or bone marrow transplantation (BMT), among others.<sup>5</sup> Immunosuppressive regimens after solid organ transplantation typically include glucocorticoids, an antimetabolite (mycophenolate mofetil or azathioprine) and a calcineurin inhibitor (tacrolimus or cyclosporine).<sup>6</sup>

To this date, very few studies have evaluated the association between SOT and bronchiectasis. Most of them are limited to paediatric population<sup>7,8</sup> or adults after renal transplantation,<sup>9</sup> mainly focusing mycophenolate as a possible cause.<sup>10,11</sup> Similarly, there are only a few case reports regarding the relationship between bronchiectasis and bone marrow transplantation,<sup>12</sup> mostly limited to the assessment of bronchiectasis as a manifestation of Graft vs Host Disease.<sup>13,14</sup>

The objective of this study is to characterize a population with bronchiectasis due to immunosuppression after SOT or BMT.

This retrospective, observational, single-centre study included patients followed at Bronchiectasis Clinic of Bellvitge University Hospital from April 2022 to February 2023. Inclusion criteria were a diagnosis of bronchiectasis after SOT or BMT, including a confirming CT scan. Exclusion criteria were bronchiectasis diagnosed before transplantation, the absence of bronchiectasis in CT scan after transplantation or the absence of a confirming CT scan.

Demographic and clinical data were registered. Data were stratified for statistical analysis by the presence of chronic bronchial infection and by type of transplantation. Patients' data were collected as part of a larger retrospective study approved by local ethics committee (CEIC-2907).

Fifteen patients were included; 66.7% were women. Median age was  $67 \pm 12$  years. Table 1 shows demographic and clinical data. The most common type of transplantation was renal (46.7%) and 3 patients underwent BMT (20%). Mean time from trans-

plantation to bronchiectasis' diagnosis was 134 months. The most commonly used immunosuppressive drugs were Mycophenolate (73.3%), oral glucocorticoids (60%) and Tacrolimus (53.3%). The majority of patients had chronic bronchial infection (CBI) (53.3%) with *Pseudomonas aeruginosa* being the most frequently identified microorganism (62.5%). Bronchiectasis severity index (BSI) mean score was 7.7 (moderate severity) and the E-FACED's was 2.6 (moderate severity).

Patients with CBI were more likely to have undergone heart transplantation or BMT compared to those without CBI. Patients with CBI were diagnosed with bronchiectasis earlier than patients without CBI ( $90 \pm 91$  vs  $184 \pm 85$  months;  $p=0.06$ ). Moreover, patients with CBI had a higher severity of bronchiectasis measured by the BSI ( $9.4 \pm 4.3$  vs  $5.7 \pm 2.8$  points;  $p=0.078$ ).

Table 2 shows comparison by type of transplantation. Patients who underwent BMT were younger ( $55 \pm 10$  vs  $70 \pm 11$  years;  $p=0.048$ ) and had worse lung function than those who underwent SOT (FEV1  $59.7 \pm 20.8\%$  vs  $102.5 \pm 23.2\%$ ;  $p=0.014$ ). BMT patients were diagnosed with bronchiectasis earlier than those with SOT ( $35 \pm 20$  months vs  $158 \pm 94$  months;  $p=0.046$ ). Also, there was a non-significant tendency for patients who underwent BMT to be more likely to have CBI compared to those who underwent SOT (100% vs 42.7%;  $p=0.2$ ) and to have more severe bronchiectasis measured by BSI ( $9.7 \pm 6.1$  vs  $7.2 \pm 3.5$  points;  $p=0.355$ ).

This study highlights that secondary immunosuppression after SOT and BMT is a serious and poorly studied cause of bronchiectasis, showing high severity scores and CBI rates, especially in those with BMT. There is limited data on this regard, so the true impact of immunosuppression in bronchiectasis is not completely understood. The largest series to date was published in 2015 by Dury et al.,<sup>9</sup> which included 46 patients who had undergone renal transplantation in 14 French centres. There was no data regarding the severity of bronchiectasis neither about non-renal transplantation in these series to compare with our sample.

Compared to observations from European and Spanish bronchiectasis registries,<sup>2–4</sup> our sample had a similar median age, gender distribution, smoking history and prevalence of airway obstruction. The severity of bronchiectasis was higher in our sample compared to the European registries and similar to the Spanish registry RIBRON. The prevalence of CBI was higher compared to these registries, with *P. aeruginosa* being the most frequently identified microorganism in both.

Furthermore, most studies and clinical trials tend to exclude patients who have undergone SOT or BMT. Therefore, management strategies are extrapolated from general bronchiectasis recommendations, which may not be adequate for all immunocompromised patients. In addition, we observed a significant diagnostic delay on these patients, thus effective bronchiectasis treatments such as physiotherapy and chronic antibiotics may be started later. In this regard, we speculate that a thoracic CT scan and a prompt refer-

**Table 1**  
Clinical data of the study patients and comparison by the presence of CBI.

	All (n = 15)	Without CBI (n = 7)	With CBI (n = 8)	p-Value
Age (mean, SD)	66.9 (11.9)	67.5 (12.3)	67.5 (12.3)	0.852
Women (n, %)	10 (66.7%)	4 (57.1%)	4 (50%)	0.608
Smoking (n, %)				
Never smokers	9 (60.0%)	4 (57.1%)	5 (62.5%)	>0.999
Former smokers	5 (33.3%)	2 (28.6%)	3 (37.5%)	
Current smokers	1 (6.7%)	1 (14.3%)	0 (0%)	
Type of transplantation (n, %)				
Heart	2 (13.3%)	0 (0%)	2 (37.5%)	<b>0.038</b>
Liver	3 (20.0%)	3 (42.9%)	0 (0%)	
Kidney	7 (46.7%)	4 (57.1%)	3 (37.5%)	
BMT	3 (20.0%)	0 (0%)	3 (37.5%)	
Months from transplantation to bronchiectasis diagnose (mean, SD)	134 (98)	184 (85)	90 (90.5)	<b>0.061</b>
FEV <sub>1</sub> (mean, SD)	93.3 (28.5)	96.0 (40.4)	90.7 (44.7)	0.744
FEV <sub>1</sub> /FVC (mean, SD)	71.1 (11.2)	70.6 (26.3)	71.6 (27.8)	0.876
Dyspnoea mMRC (median, IQR <sup>7</sup> )	2 (1)	1 (1.5)	2 (1)	0.467
N° lobes (median, IQR)	3 (3)	3 (2)	3 (2)	>0.999
Exacerbations in the previous year (median, IQR)	1 (2)	1 (0.5)	1 (2)	0.569
Admissions in the previous year (median, IQR)	0 (1)	0 (0)	1 (1)	0.282
Microorganism IBC (n, %)				
None	7 (46.7%)	7 (100%)	0 (0)	<b>&lt;0.001</b>
P. aeruginosa	5 (33.3%)	0	5 (62.5%)	
H. influenzae	3 (20.0%)	0	3 (37.5%)	
Azithromycin (n, %)	3 (20.0%)	1 (14.3%)	2 (25%)	>0.999
Inhaled antibiotic (n, %)	5 (33.3%)	0 (0%)	5 (62.5%)	<b>0.026</b>
Inhaled treatment (n, %)				
None	6 (40.0%)	4 (57.1%)	2 (25%)	0.145
LABA <sup>8</sup> + LAMA	1 (6.7%)	1 (14.3%)	0 (0)	
LABA + ICS	4 (26.7%)	2 (28.6%)	2 (25%)	
LABA + LAMA + ICS	4 (26.7%)	0 (0)	4 (50%)	
Oral glucocorticoids (n, %)	9 (60.0%)	3 (42.9%)	6 (75%)	0.315
Tacrolimus (n, %)	8 (53.3%)	2 (28.9%)	6 (75%)	0.132
Mycophenolate (n, %)	11 (73.3%)	6 (85.7%)	5 (62.5%)	0.569
Everolimus (n, %)	1 (6.7%)	0 (0%)	1 (6.7%)	>0.999
BSI (mean, SD)	7.7 (4.0)	5.7 (2.8)	9.4 (4.3)	<b>0.078</b>
E-FACED (mean, SD)	2.6 (1.5)	2 (0.8)	3.1 (1.9)	0.168

CBI: chronic bronchial infection; SD: standard deviation; BMI: bone marrow transplantation; FEV<sub>1</sub>: forced expiratory volume in the 1st second; FVC: forced vital capacity; mMRC: dyspnoea modified scale of the Medical Research Council; IQ: interquartile range; LABA: long-acting beta agonist; LAMA: long-acting antimuscarinic; ICS: inhaled glucocorticoid; BSI: bronchiectasis severity index.

Bold values denote statistical significance at the p <0.05 level.

**Table 2**  
Comparison by type of transplantation.

	BMT (n = 3)	SOT (n = 12)	p-Value
Age (mean, SD)	55.0 (9.5)	69.9 (10.8)	<b>0.048</b>
Months from transplantation to bronchiectasis diagnose (mean, SD)	35.3 (20.0)	158.3 (93.8)	<b>0.046</b>
FEV <sub>1</sub> (mean, SD)	59.7 (20.8)	102.5 (23.2)	<b>0.014</b>
FEV <sub>1</sub> /FV (mean, SD)	64.0 (9.5)	73.0 (11.3)	0.233
CBI (n, %)	3 (100%)	5 (42.7%)	0.200
Mycophenolate (n, %)	3 (100%)	1 (8.3%)	<b>0.009</b>
BSI (media, DE)	9.7 (6.1)	7.2 (3.5)	0.355
E-FACED (media, DE)	2.7 (2.5)	2.6 (1.4)	0.937

BMT: bone marrow transplantation; SOT: solid organ transplantation; SD: standard deviation; FEV<sub>1</sub>: forced expiratory volume in the 1st second; FVC: forced vital capacity; CBI: chronic bronchial infection; BSI: bronchiectasis severity index.

Bold values denote statistical significance at the p <0.05 level.

ral to respiratory specialists in all patients with compatible clinical syndrome and/or recurrent lung infections after SOT or BMT would probably improve patient outcomes.

Finally, patients who undergo BMT are younger and have a more serious disease than those who undergo SOT. Consequently, bronchiectasis in these patients should be suspected, studied and, if necessary, referred promptly to the respiratory specialist for proper examination, treatment and follow-up.

Our study has several limitations related to the small sample size and retrospective nature. However, to this date, this is the first study specifically assessing the severity and clinical characteristics

of post-transplant bronchiectasis, both SOT and BMT. Our results are robust and highlight the importance of considering this condition in post-transplant patients to prevent diagnostic delays and inadequate treatment.

Bronchiectasis due to transplant-related immunosuppression is an uncommon but serious disease. There are very limited data available regarding the characteristics and proper management of these patients, which may contribute to diagnosis and treatment delay. Further research and larger studies are needed to better characterize these patients and to develop effective diagnostic and therapeutic strategies.

## Funding

No external financing has been needed for this study.

## Authors' contributions

David Rodríguez-Plaza and Guillermo Suárez-Cuartín wrote the manuscript. All authors reviewed the manuscript.

## Conflicts of interest

David Rodríguez-Plaza, Ane Martínez de las Fuentes, Javier Burgos, Núria Sabé and Salud Santos declare no conflicts of interest.

Guillermo Suárez-Cuartín has received grants from Grifols, travel grants from Teva and Pari and participated in advisory boards for Insmad.

## References

- De la Rosa D, Prados C. Epidemiology and geographic diversity of Bronchiectasis. *Open Respir Arch*. 2020;2:215–25, <http://dx.doi.org/10.1016/j.opresp.2020.05.008>.
- Chalmers JD, Polverino E, Crichton ML, Ringshausen FC, De Soyza A, Vendrell M, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). *Lancet Respir Med*. 2023;11:637–49, [http://dx.doi.org/10.1016/S2213-2600\(23\)00093-0](http://dx.doi.org/10.1016/S2213-2600(23)00093-0).
- Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. *Ann Am Thorac Soc*. 2015;12:1764–70, <http://dx.doi.org/10.1513/AnnalsATS.201507-472OC>.
- Martínez-García MA, Villa C, Dobarganes Y, Girón R, Maíz L, García-Clemente M, et al. RIBRON: el registro español informatizado de bronquiectasias. Caracterización de los primeros 1912 pacientes. *Arch Bronconeumol*. 2021;57:28–35, <http://dx.doi.org/10.1016/j.arbres.2019.12.021>.
- Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies, an overview. *Ann Allergy Asthma Immunol*. 2021;127:617–26, <http://dx.doi.org/10.1016/j.anai.2021.08.413>.
- Van Sandwijk MS, Bemelman FJ, Ten Berge IJM. Immunosuppressive drugs after solid organ transplantation. *J Med*. 2013;71:281–9.
- Pijnenburg MW, Cransberg K, Wolff E, Bouquet J, Merkus PJFM. Bronchiectasis in children after renal or liver transplantation: a report of five cases. *Pediatr Transplant*. 2004;8:71–4, <http://dx.doi.org/10.1046/j.1397-3142.2003.00130.x>.
- Cransberg K, Cornelissen EAM, Darvin J-C, Van Hoeck KJM, Lilien MR, Stijnen T, et al. Improved outcome of pediatric kidney transplantations in the Netherlands – effect of the introduction of mycophenolate mofetil? *Pediatr Transplant*. 2005;9:104–11, <http://dx.doi.org/10.1111/j.1399-3046.2005.00271.x>.
- Dury S, Colosio C, Etienne I, Anglicheau D, Merieau E, Caillard S, et al. Bronchiectasis diagnosed after renal transplantation: a retrospective multicenter study. *BMC Pulm Med*. 2015;15:141, <http://dx.doi.org/10.1186/s12890-015-0133-9>.
- Rook M, Postma DS, van der Jagt EJ, Van Minnen CA. Mycophenolate mofetil and bronchiectasis in kidney transplant patients: a possible relationship. *Transplantation*. 2006;81:287–9, <http://dx.doi.org/10.1097/01.tp.0000188638.28003.96>.
- Boddana P, Webb LH, Unsworth J, Brealey M, Bingham C, Harper SJ. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil treated renal transplant recipients: an emerging clinical phenomenon? *Clin Transplant*. 2011;25:417–9, <http://dx.doi.org/10.1111/j.1399-0012.2010.01255.x>.
- Morehead RS. Bronchiectasis in bone marrow transplantation. *Thorax*. 1997;52:392–3, <http://dx.doi.org/10.1136/thx.52.4.392>.
- Phatak TD, Maldjian PD. Progressive bronchiectasis as a manifestation of chronic graft versus host disease following bone marrow transplantation. *Radiol Case Rep*. 2008;3:137, <http://dx.doi.org/10.2484/rcr.v3i1.137>.
- Tanawuttiwat T, Harindhanavudhi T. Bronchiectasis: pulmonary manifestation in chronic graft versus host disease after bone marrow transplantation. *Am J Med Sci*. 2009;337:292, <http://dx.doi.org/10.1097/MAJ.0b013e31818c2a10>.

David Rodríguez-Plaza<sup>a,\*</sup>, Ane Martínez-De las Fuentes<sup>a</sup>,  
Javier Burgos<sup>a</sup>, Núria Sabé<sup>b</sup>, Salud Santos<sup>a</sup>,  
Guillermo Suárez-Cuartín<sup>a</sup>

<sup>a</sup> *Department of Pulmonary Medicine, Bellvitge University Hospital, Spain*

<sup>b</sup> *Department of Infectious Diseases, Bellvitge University Hospital, Spain*

\* Corresponding author.

E-mail address: [davidrodriguezplaza@gmail.com](mailto:davidrodriguezplaza@gmail.com)  
(D. Rodríguez-Plaza).